|1.||Hoff, Paulo M: 1 article (05/2004)|
|2.||Zukowski, Thomas: 1 article (05/2004)|
|3.||Berghorn, Elmer: 1 article (05/2004)|
|4.||Hausheer, Frederick: 1 article (05/2004)|
|5.||Newman, Robert A: 1 article (05/2004)|
|6.||Ni, Dan: 1 article (05/2004)|
|7.||Abbruzzeese, James: 1 article (05/2004)|
|8.||Madden, Timothy: 1 article (05/2004)|
|9.||Hutto, Toni: 1 article (05/2004)|
|10.||Johansen, Mary: 1 article (05/2004)|
05/01/2004 - "Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors."
08/01/1997 - "Gamma-methylene-10-deazaaminopterin (MDAM), a unique dihydrofolate reductase inhibitor, has demonstrated antitumor activity against a broad spectrum of human solid tumors in preclinical studies. "
08/01/1997 - "Novel high-performance liquid chromatographic assay using fluorescence detection for the quantitation of plasma gamma-methylene-10-deazaaminopterin and its major metabolite, 7-hydroxy-gamma-methylene-10-deazaaminopterin, in patients with solid cancers in a phase I trial."
05/01/2004 - "To determine the maximum tolerated dose (MTD) of gamma-methylene-10-deazaaminopterin (MDAM), a unique antifolate structurally similar to methotrexate (MTX), in the treatment of patients with solid tumors and to characterize toxicity and pharmacokinetic profiles of MDAM administered intravenously for five consecutive days repeated every 21 days. "
|1.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|2.||7- hydroxy- gamma- methylene- 10- deazaaminopterin